The Cancer Research UK Birmingham Centre is managed under the umbrella of Birmingham Health Partners, which unites the University of Birmingham with key local clinical partners. Top-level oversight is provided by the Cancer Strategy Group, which has representation from all key partners.
Meeting twice a year, the non-executive Cancer Strategy Board chaired by Professor Paul Moss, Professor of Haematology and Deputy Head of the University's College of Medical and Dental Sciences, are configured to:
- oversee/develop/adjust/approve and drive the strategy of the Centre, including training programmes;
- provide a decision-making forum to enable the Centre to take advantage of strategically important opportunities;
- discuss and agree strategy for recruitments to the Centre/ University;
- provide assurance for the delivery of the Centre strategy and objectives;
- provide assurance that the Centre’s progress in delivering branding, press and research engagement activities meet CRUK’s expectations;
- review the Centre’s performance and its contribution to the Cancer Research UK Centres network;
- review top-level financial opportunities (e.g. leveraging funding) and challenges;
- review key initiatives put forward by CRUK, Research Councils, the NHS and other bodies funding cancer research and the Centre’s responses to them.
Most Centre management decisions are taken by the CRUK Birmingham Centre Management Group, co-chaired by the Centre’s Scientific Director Professor Ben Willcox, and Clinical Director Professor Gary Middleton. In addition, a Training Advisory Group chaired by Dr Clare Davies is responsible for managing the Centre PhD training programme.
The Centre Management Group has clinical and non-clinical representation from across the Centre themes. Members include:
There is close alignment with the Birmingham Experimental Cancer Medicine Centre (ECMC) management, with reciprocal involvement of ECMC and Centre Directors and theme leads in respective management structures, ensuring coordinated planning of fundamental and translational cancer research programmes. We work closely with our partner NHS Trusts on initiatives of joint relevance, such as the University Hospitals Birmingham Radiotherapy Research Priorities.